DRUGS firm AstraZeneca is ready to roll out Oxford University’s coronavirus vaccine from September.
The company has pledged one billion doses of the AZD1222 jab that will be distributed on a global scale.
⚠️ Read our coronavirus live blog for the latest news & updates
The firm has however stated that the vaccine may not work, but clinical trials are currently underway to determine this.
So far in the UK over 35,000 people have died from the coronavirus and the new vaccine could provide hope as to when the world will find a way out of the pandemic.
The developments come after Prime Minister Boris Johnson said that a vaccine "may never be found", with Sir Patrick Vallance having also said last week that the development of an effective vaccine could not be guaranteed.
AstraZeneca recently joined forces with the UK government in order to progress the vaccine efforts and it will supply the UK from September.
Last month phases one and two of the trial started which assessed safety, immunogenicity and efficacy in over 1,000 healthy volunteers.
Data from the trial is set to be released soon and it could lead to late-stage trials in other parts of the world.
In April those working on the vaccine said they were 80 per cent confident they had a solution.
Professor Sarah Gilbert said it would be ready by September and others on the team said they would not have to wait for the usual six month confirmation period.
Dr. Alexander Douglas, the leader of the research group at Oxford which has developed the manufacturing method, said: "We have been preparing for large-scale manufacturing of our vaccine candidate since February.
"This funding enables manufacturing to start immediately, and so will make vaccine available as soon as possible, while adhering to the most stringent safety standards. The methods developed here in the UK will also enable the production of vaccine for other countries."
Pascal Soriot, chief executive officer at the firm said the pandemic is a global tragedy and that “we need to defeat the virus together” before it inflicts long-lasting economic damage.
The firm has so far received $1 billion from the US Biomedical Advanced Research and Development Authority which will go towards the distribution of the vaccine.
The next stages of the vaccine will be in the form of a clinical trial with 30,000 participants and a pediatric trial.
CORONAVIRUS CRISIS – STAY IN THE KNOW
Don't miss the latest news and figures – and essential advice for you and your family.
To receive The Sun's Coronavirus newsletter in your inbox every tea time, sign up here.
To follow us on Facebook, simply 'Like' our Coronavirus page.
Get Britain's best-selling newspaper delivered to your smartphone or tablet each day – find out more.
Source: Read Full Article